Key stakeholder perspectives on implementation of mHealth and NCD- related interventions in Kenyan Emergency Departments
Abstract
Background: Emergency Department (ED) populations are a high-risk group that are opportune for interventions targeting NCDs and NCD risk factors, like tobacco use. Mobile health (mHealth)interventions such as Text2Quit, a novel text message-based mHealth tool addressing tobacco cessation in the US, have demonstrated effectiveness for tobacco cessation and for ED-based mHealth interventions in High Income Countries (HIC). To successfully adapt and implement such mHealth interventions in limited resource settings like African EDs, it is essential to examine the implementation climate and engage key stakeholders. These implementers provide invaluable insight to understand healthcare system level factors that affect adoption, implementation and maintenance of the interventions.
Methods: We conducted 12 semi-structured key informant interviews (KIIs) with ED administrators and staff including 2 departmental heads, 5 medical doctors, 3 nurses, and 2 clinical officers at a national referral hospital in Kenya. This was guided by RE-AIM framework indicators of “Adoption”, “Implementation”, and “Maintenance” (eg feasibility of intervention integration, and suggestions to improve implementation). Interviews were conducted in English, recorded, professionally transcribed and translated, and analyzed using a constant comparative analysis approach, according to grounded theory principles.
Findings: Key informants were positive about the adoption of them Health intervention in Kenyan EDs…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.